Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$174.0M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1932.93%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$458.5M
Q3 2024
Cash
Q3 2024
P/E
-1.512
Nov 29, 2024 EST
Free Cash Flow
-$21.83M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $351.4M $48.63M $0.00 $0.00
YoY Change -100.0% 622.49%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $351.4M $48.63M $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $49.92M $48.71M $45.79M $21.64M $4.440M $2.800M
YoY Change 2.47% 6.4% 111.58% 387.39% 58.57%
% of Gross Profit
Research & Development $114.2M $81.94M $167.2M $38.02M $10.17M $6.675M
YoY Change 39.43% -51.0% 339.75% 273.87% 52.36%
% of Gross Profit
Depreciation & Amortization $416.0K $260.0K $29.00K $0.00 $0.00 $0.00
YoY Change 60.0% 796.55%
% of Gross Profit
Operating Expenses $164.2M $130.7M $213.0M $59.66M $14.61M $9.477M
YoY Change 25.65% -38.66% 256.99% 308.43% 54.14%
Operating Profit -$164.2M -$130.7M $138.4M -$11.03M -$14.61M -$9.477M
YoY Change 25.65% -194.42% -1354.55% -24.49% 54.14%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $29.22M $11.15M $213.0K $80.00K $570.0K $410.0K
YoY Change 162.08% 5135.21% 166.25% -85.96% 39.02%
% of Operating Profit 0.15%
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$134.9M -$119.5M $138.6M -$10.95M -$14.03M -$9.060M
YoY Change 12.92% -186.22% -1365.66% -21.98% 54.9%
Income Tax $1.018M -$3.590M $17.40M
% Of Pretax Income 12.56%
Net Earnings -$136.0M -$115.9M $121.2M -$10.95M -$14.03M -$9.064M
YoY Change 17.3% -195.64% -1207.06% -22.0% 54.83%
Net Earnings / Revenue 34.49% -22.51%
Basic Earnings Per Share -$1.63 -$1.39 $1.46 -$0.51 -$1.39
Diluted Earnings Per Share -$1.63 -$1.39 $1.37 -$0.51 -$1.39 -$112.2K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $578.1M $646.7M $764.4M $850.1M $21.70M $34.50M
YoY Change -10.61% -15.39% -10.08% 3817.51% -37.1%
Cash & Equivalents $143.8M $188.5M $764.4M $850.1M $21.70M $34.50M
Short-Term Investments $434.3M $458.2M
Other Short-Term Assets $12.35M $14.21M $8.028M $7.500M $200.0K $200.0K
YoY Change -13.11% 77.04% 7.04% 3650.0% 0.0%
Inventory
Prepaid Expenses
Receivables $0.00 $5.800M
Other Receivables $0.00 $0.00
Total Short-Term Assets $590.5M $660.9M $772.4M $863.5M $21.90M $34.70M
YoY Change -10.66% -14.43% -10.55% 3842.92% -36.89%
Property, Plant & Equipment $3.117M $4.094M $184.0K $0.00 $0.00 $100.0K
YoY Change -23.86% 2125.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.396M $1.692M $305.0K $100.0K $100.0K $100.0K
YoY Change -17.49% 454.75% 205.0% 0.0% 0.0%
Total Long-Term Assets $4.513M $5.786M $489.0K $100.0K $200.0K $200.0K
YoY Change -22.0% 1083.23% 389.0% -50.0% 0.0%
Total Assets $595.0M $666.7M $772.9M $863.6M $22.10M $34.90M
YoY Change
Accounts Payable $4.252M $2.551M $4.534M $100.0K $500.0K $400.0K
YoY Change 66.68% -43.74% 4434.0% -80.0% 25.0%
Accrued Expenses $28.12M $15.83M $49.78M $14.40M $1.900M $1.400M
YoY Change 77.69% -68.2% 245.67% 657.89% 35.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.38M $18.48M $56.88M $315.8M $2.400M $1.800M
YoY Change 75.21% -67.52% -81.99% 13058.33% 33.33%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.400M $7.658M $5.932M $0.00 $100.0K $100.0K
YoY Change -3.37% 29.1% -100.0% 0.0%
Total Long-Term Liabilities $7.400M $7.658M $5.932M $0.00 $100.0K $100.0K
YoY Change -3.37% 29.1% -100.0% 0.0%
Total Liabilities $39.78M $26.14M $62.82M $315.8M $2.500M $1.900M
YoY Change 52.19% -58.39% -80.11% 12532.0% 31.58%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 83.39M 83.25M 82.82M 21.59M 10.09M
Diluted Shares Outstanding 83.39M 83.25M 88.25M 21.59M 10.09M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $263.1 Million

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The firm is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). The company is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Industry: Pharmaceutical Preparations Peers: ANI PHARMACEUTICALS INC Cara Therapeutics, Inc. COLLEGIUM PHARMACEUTICAL, INC Edgewise Therapeutics, Inc. Esperion Therapeutics, Inc. Evolus, Inc. JOHNSON & JOHNSON Nuvation Bio Inc. PHIBRO ANIMAL HEALTH CORP Tricida, Inc.